IPG 001
Alternative Names: IPG-001Latest Information Update: 28 Jan 2025
At a glance
- Originator Nanjing Amifei Biopharmaceutical Technology
- Developer Immunophage Biotech; Nanjing Amifei Biopharmaceutical Technology
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Breast cancer; Liver cancer; Multiple sclerosis; Systemic lupus erythematosus
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for clinical-Phase-Unknown development in Autoimmune-disorders in China
- 28 Jan 2025 No recent reports of development identified for clinical-Phase-Unknown development in Breast-cancer in China
- 28 Jan 2025 No recent reports of development identified for clinical-Phase-Unknown development in Liver-cancer in China